Biogen Idec, Inc. (BIIB) Misses Q1 EPS by 8c; Guides FY12
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.65 --0%
EPS Growth %: -56.8%
Financial Fact:
Product: 2.54B
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -56.8%
Financial Fact:
Product: 2.54B
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q1 EPS of $1.40, $0.08 worse than the analyst estimate of $1.48. Revenue for the quarter came in at $1.29 billion versus the consensus estimate of $1.31 billion.
Sees FY12 adj-EPS above $6.15, which compares to the Street estimate of $6.19.
Expecting to buyback an additional $500 million in common shares.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Sees FY12 adj-EPS above $6.15, which compares to the Street estimate of $6.19.
Expecting to buyback an additional $500 million in common shares.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic jumps on earnings beat and raised guidance
- SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
- Goldman Sachs starts Viridien at Buy on exploration recovery, shares rise
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Stock BuybacksRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
